Rolvedon (Hanmi Pharm) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, And Forecasts, 2020-2025, 2025-2030F, 2035F

(MENAFN- GlobeNewsWire - Nasdaq) Opportunities in the rolvedon market include rising demand for patient-friendly oncology drugs, focus on improving treatment adherence, and growing investments in biologics. Expansion of outpatient cancer care and increased cancer prevalence enhance market growth. Asia-Pacific leads in growth potential, while tariffs influence costs.

Dublin, March 13, 2026 (GLOBE NEWSWIRE) -- The "Rolvedon Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets's offering.

The historic growth of the Rolvedon market has been driven by increased chemotherapy use, rising cases of treatment-induced neutropenia, acceptance of colony-stimulating factors, expansion of oncology treatment centers, and established supportive care guidelines.

Future growth is anticipated to stem from the rising demand for patient-friendly oncology drugs, enhanced treatment adherence, expansion of outpatient cancer care, investments in long-acting biologics, and the development of differentiated G-CSF formulations. Key trends include the adoption of long-acting G-CSF therapies, infection risk reduction during chemotherapy, a preference for reduced dosing frequency, and enhanced monitoring of neutrophil recovery.

The rising incidence of cancer is expected to propel the Rolvedon market forward. Cancer prevalence is increasing due to aging populations, lifestyle choices, environmental factors, genetic predisposition, and better diagnostic methods. Rolvedon aids cancer patients by boosting white blood cell production and increasing neutrophil counts to minimize infection risks during chemotherapy and strengthen the immune system. According to a November 2024 report from PubMed, global cancer cases are predicted to reach 35.3 million by 2050, up 76.6% from the 2022 figure of 20 million, thereby fueling growth in the Rolvedon market.

Leading companies in the Rolvedon market are developing innovative biologic medications to address the demand for precise, personalized, and less harmful treatments. In April 2023, Spectrum Pharmaceuticals, Inc. marked a milestone with Rolvedon (eflapegrastim-xnst), a biologic therapy in oncology care. Designed to decrease infection incidences in adults with non-myeloid cancers on myelosuppressive chemotherapy, Rolvedon's long-acting G-CSF formulation enhances neutrophil recovery and chemotherapy tolerance. With CMS's assignment of J-code (J1449), Rolvedon is poised to access a significant market opportunity, estimated at $2 billion.

In April 2023, Assertio Holdings Inc. acquired Spectrum Pharmaceuticals, Inc., enhancing its oncology portfolio and strengthening market access. Meanwhile, Hanmi Pharm Co Ltd continues to be a major player in the field. North America held the largest market share in 2025, while Asia-Pacific is expected to experience rapid growth. The market spans regions including Asia-Pacific, Europe, North America, South America, Middle East, and Africa, covering countries such as the USA, Canada, China, India, and Japan.

Tariffs are affecting the Rolvedon market by increasing costs related to imported biologics, equipment, and packaging materials. This pressure is particularly felt in North America and Europe due to reliance on international supply chains, whereas Asia-Pacific faces cost challenges in contract manufacturing. Nonetheless, tariffs are prompting increased local biologics manufacturing, supply chain integration, and domestic sterile capabilities investment.

The Rolvedon market report is part of a series offering insights into market size, regional dynamics, competitor analysis, segment details, trends, and opportunities. The comprehensive report provides an in-depth analysis for thriving in the Rolvedon industry.

Rolvedon is utilized to reduce infection risks for chemotherapy patients by promoting neutrophil production. It serves various channels such as hospital, retail, and online pharmacies, catering to hospitals, clinics, and homecare settings. The market encompasses sales of injectables, biologic drugs, diagnostic tools, and related services, measured at 'factory gate' values.

Reasons to Purchase:

• Gain a global perspective with the most comprehensive market report spanning 16 geographies.
• Analyze the impact of macro factors including geopolitical events, trade policies, tariffs, inflation, and regulatory changes.
• Formulate regional and country-specific strategies using localized data and analysis.
• Identify investment opportunities in high-growth segments.
• Leverage forecast data, market drivers, and trends to outperform competitors.
• Understand customer preferences through end-user analysis.
• Benchmark against competitors based on market share, innovation, and brand positioning.
• Evaluate the total addressable market (TAM) to assess market potential.
• Support internal and external presentations with high-quality, reliable data and analysis.
• Receive regular data updates with an accompanying Excel data sheet for ease of extraction and analysis.

Report Scope:

• Clinical Indication: Primary Indication, Patient Population, Treatment Context
• Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
• End User: Hospitals and Clinics, Specialty Centers, Homecare Settings, Research and Academic Institutions

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN13032026004107003653ID1110857163